The work we do here at the centre would not happen without the support of our partners.
The ARUK Centre for Epidemiology , also based at the University, undertakes a major research programme focussing on clinically important questions in musculoskeletal disease that require a robust epidemiological approach. Their areas of research focus include the occurrence and progression of disease, the effectiveness and safety of treatment, and the impact of disease and treatment on quality of life.
The NIHR Manchester Biomedical Research Centre (BRC) connects world-leading researchers based at The University of Manchester and four NHS Trusts in Greater Manchester. The Musculoskeletal theme is led by Professor Anne Barton and its main focus is to identify biomarkers to predict outcomes and personalise treatment.
Professor Soumya Raychaudhuri who has a 20% appointment in the centre but is largely based in Boston. His main focus is the exploitation of multiple types of high content data in both translational and functional genomics being generated in the CfGG. Staff are encouraged to spend time in Boston to develop advanced skills in statistical genomics and genetics.
Arthritis Research UK invests in breakthrough treatments, the best information and vital support for everyone affected by arthritis.
The MCCIR was established in 2013 in a £15m partnership between UoM, GSK and Astrazeneca, bringing academia and industry together in a unique pre-competitive partnership. We benefit greatly from access to the excellent MCCIR FACS facility.
All of our projects benefit from input from people with direct experience of musculoskeletal conditions. These include people living with musculoskeletal conditions as well as those who care for them. Members of the RUG contribute either individually to specific projects, or as a group. They review our research questions, methodology and circulation strategies.
Following a successful funding bid, three very successful CRFs have been combined to become the ‘One Manchester’ CRF (MCRF). MCRF provides 54 research beds/chairs and 21 outpatient rooms to support Experimental Medicine in all disease areas.
The SCRC provides a platform to identify and characterise therapeutic target cells so we can discover treatments for many of the most challenging diseases and degenerative conditions in the world today.
The Stoller Centre aims to identify biomarkers that could be used to diagnose or inform treatment of diseases such as RA, JIA and PsA. The centre helps to industrialise the process of identifying protein biomarkers that indicate the presence of a disease or the likelihood that a patient will respond to a specific therapy for their disease.
The MMPathIC provides an environment to facilitate the translation of stratified medicine and biomarker research into novel diagnostics and molecular pathology tests that can be implemented within the NHS.